Tagged with Treatment

China This week, China has fast-tracked approval for 48 “much-needed medicines.” Regulators gave special consideration to new treatments for rare diseases as well as drugs that target serious, life-threatening illnesses, like cancer. Authorities were made to sit up and listen following the box office success of a low budget film called “Dying to…

Bulgaria Ekaterina Karpuzova, country commercial lead pharmaceuticals at Bayer Bulgaria, explains how the national healthcare system has evolved over the last few years as well as demonstrates the commitment of Bayer Bulgaria to supporting the impact and quality of its solutions through value-based evidence. After starting in Bayer Bulgaria, you went…

Taiwan Du-Shieng Chien, President & CEO of TaiRx, a Taiwan-based biopharmaceutical company focused on unmet medical needs, provides insights into the recent development of CVM 1118, a revolutionary cancer treatment targeting breakthrough mechanisms to tackle tumor development and the first drug of its kind to have already started clinical trials in…

Singapore Eli Lilly and Company General Manager of South ASEAN, Dr. Faiz Ansari speaks about the expanded scope of his role,  Lilly’s pipeline, and the approach that Lilly has taken to support healthcare delivery and improve patients‘ access to treatment and to support programs in a region that is so inherently…

Pharma Ahead of the imminent acquisition of Baxalta by Shire, country managing director Italy Fabio Andreola shares his perspective on the rare-disease environment in Italy and how Baxalta will contribute to making the new combined company the undisputed leader in the treatment of rare diseases. How would you assess the Italian…

Pharma Novo Nordisk Hungary GM Zsolt Jozsa highlights the growing prevalence of diabetes in Hungary, the gap in treatment options that the company is striving to close with Tresiba and Xultophy, and the limitations of Hungary’s regulatory framework. Zsolt, you took over the helm of Novo Nordisk Hungary in 2012, after…

Pharma The Netherlands is clearly a fertile environment for its 2,200 life science and medtech companies. However, the Dutch ambition to be a frontrunner in new healthcare challenges also comprises an overall approach to treating patients. Aging population, chronic disease, and innovative pharmaceutical treatments’ role in extending patients’ life expectancies have…

Pharma Sean Connor, General Manager Benelux and UK/ROI for ALK, details the company’s strategy both in terms of products and therapeutic areas and provides us with his assessment of Netherlands regulatory environment and market access. You have been General Manager for the UK and ROI since 2013, and, in January 2015,…

diabetes treatment Novo Nordisk’s market access and public affairs director discusses the state of diabetes management in Mexico, highlighting the government’s recent commitment to tackle this public health issue and the company’s contribution to the dialogue. You were appointed as the director for public affairs two years ago, and recently of market…